Overview
Khaled M. El-Shami, M.B.Ch.B., Ph.D., is a medical oncologist at Johns Hopkins Kimmel Cancer Center at Sibley Memorial Hospital, as well as an assistant professor of oncology in the Division of Hematologic Malignancies at Johns Hopkins University School of Medicine. Listen to Dr. El-Shami's Cancer Matters podcast episode to learn more about his work. Dr. El-Shami's clinical interests are in hematologic malignancies, including leukemias, lymphomas and myelomas.. Dr. El-Shami graduated from Alexandria University Faculty of Medicine in Alexandria, Egypt, where he did a residency in the Department of Neurosurgery. He was a Chevening Scholar as a M.S. student in molecular genetics at the University of Sussex in the United Kingdom, as well as a Sam Cohen Windhoek Scholar as a Ph.D. student in cancer immunology at the Weizmann Institute in Israel. Dr. El-Shami also completed a residency in internal medicine at George Washington University School of Medicine, a fellowship in tumor immunology and biology at the National Cancer Institute, and a fellowship in medical oncology at Johns Hopkins University School of Medicine. Dr. El-Shami previously served as faculty at Georgetown University and George Washington University. Dr. El-Shami has been named a Top Doctor by Washingtonian Magazine for several years. Dr. El-Shami is a member of the American Association for Advancement of Science, the American Association of Cancer Research, the American Association of Immunologists, the American Society for Gene Therapy and the American Society of Clinical Oncology. Dr. El-Shami's research focus is on hematologic malignancies, including acute and chronic leukemias, myelodysplastic syndromes, myeloprolifetive neplasms and lymphomas. He has received the National Institutes of Health Clinical Research Scholars Award, an American Medical Association Seed Grant and an American Society of Clinical Oncology Merit Award.
Dr. El is rated as an Experienced provider by MediFind in the treatment of Plasmacytoma. His top areas of expertise are Large-Cell Immunoblastic Lymphoma, Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Acute Myeloblastic Leukemia without Maturation, and Bone Marrow Aspiration.
His clinical research consists of co-authoring 3 peer reviewed articles. MediFind looks at clinical research from the past 15 years.
Insurance
Accepted insurance can change. Please verify directly with the provider.
Accepted insurance plans:
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- POS
- PPO
- HMO
- POS
- PPO
- EPO
- HMO
- PPO
- INSURANCE PLAN
- MEDICARE PDP
- PPO
- HMO
- POS
- PPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- OTHER COMMERCIAL
- OTHER MEDICARE
- OTHER MEDICARE PART D
- PPO
- EPO
- HMO
- PPO
- HMO
- INDEMNITY
- POS
- PPO
- EPO
- POS
- PPO
- HMO
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE-MEDICAID PLAN
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- OTHER MEDICARE
- POS
- PPO
- OTHER MANAGED MEDICAID
- OTHER MEDICAID
- STATE MEDICAID
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER MEDICARE PART D
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER MEDICARE
- OTHER MEDICARE PART D
Locations
5255 Loughboro Road Northwest, Building B, Building B, Washington, DC 20016
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Sidney Kimmel Comprehensive Cancer Center
Carol Ann Huff, M.D., is an Associate Professor of Oncology and Medicine at the Johns Hopkins University School of Medicine and Medical Director for the Johns Hopkins Kimmel Cancer Center. After completing a Bachelor of Science in Zoology at Duke University in Durham, NC, Dr. Huff received her medical degree from Baylor College of Medicine in Houston. She completed her internship and residency in Internal Medicine at Johns Hopkins and was an Assistant Chief of Service in the Department of Medicine before completing her fellowship training in the Department of Oncology at Johns Hopkins University. Dr. Huff is a nationally-recognized expert in the treatment of multiple myeloma and amyloidosis and in the development of new biologically-based treatment strategies. She has sought to better understand the mechanisms for recurrence and the inability to cure these diseases. Through this research, the identification of a myeloma cancer stem cell has emerged, and efforts to target these cells through combination therapy in clinical trials are ongoing. In collaboration with Dr. William Matsui, Dr. Huff has identified a flow cytometric-based blood analysis for multiple myeloma patients that can be used to quantify the number of myeloma cancer stem cells and track how these cells respond to treatment. Their efforts have revealed that changes in the number of myeloma cancer stem cells can predict recurrence in myeloma patients before clinical evidence of recurrence is detectable. Using this blood analysis, as well as growth of these cells from bone marrow samples taken from patients with myeloma, they have begun studying therapeutic strategies to target these cells based on cell surface markers and enzymatic pathways that are important to the survival of myeloma stem cells. Dr. Huff is the recipient of multiple awards for clinical and teaching excellence including the Kimmel Cancer Center's Director’s Teaching Award in Oncology in both 2006 and 2012. During her medical school training, Dr. Huff was the recipient of a Howard Hughes Medical Institute-National Institutes of Health (NIH) fellowship. She has received grant support from the NIH, Multiple Myeloma Research Foundation, and Leukemia and Lymphoma Society. and LLS, and is the principal investigator of numerous investigator-initiated and industry- sponsored clinical trials. She is the author of numerous publications and book chapters not only on multiple myeloma and related disorders, but also on bone marrow transplantation and a range of topics related to internal medicine and oncology. Her current research efforts involve active collaboration with the preclinical laboratories in the development and testing phases of new therapeutic approaches, as well as a lead effort in the national African American Myeloma Consortium seeking to better understand genetic determinants of the disease. Dr. Huff is rated as a Distinguished provider by MediFind in the treatment of Plasmacytoma. Her top areas of expertise are Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Smoldering Multiple Myeloma, and Plasmacytoma.
Maryland Oncology Hematology PA
Jason Taksey is an Oncologist and a Hematologist in Columbia, Maryland. Dr. Taksey is rated as a Distinguished provider by MediFind in the treatment of Plasmacytoma. His top areas of expertise are Urothelial Cancer, Familial Prostate Cancer, Muscle Invasive Bladder Cancer, and WT1-Related Wilms Tumor Syndromes. Dr. Taksey is currently accepting new patients.
University Of Maryland Community Medical Group Inc
Harvinder Singh is a Hematologist Oncology specialist and an Oncologist in Glen Burnie, Maryland. Dr. Singh is rated as a Distinguished provider by MediFind in the treatment of Plasmacytoma. His top areas of expertise are Familial Colorectal Cancer, Pleuropulmonary Blastoma, Lung Cancer, Plasmacytoma, and Bone Marrow Aspiration. Dr. Singh is currently accepting new patients.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Distinguished
- Acute Myeloblastic Leukemia without Maturation
- Acute Myeloid Leukemia (AML)Dr. El isDistinguished. Learn about Acute Myeloid Leukemia (AML).
- Large-Cell Immunoblastic LymphomaDr. El isDistinguished. Learn about Large-Cell Immunoblastic Lymphoma.
- Myelodysplastic Syndrome (MDS)Dr. El isDistinguished. Learn about Myelodysplastic Syndrome (MDS).
- T-Cell LymphomaDr. El isDistinguished. Learn about T-Cell Lymphoma.
- Advanced
- Acute Myeloblastic Leukemia with Maturation
- Angioimmunoblastic T-cell Lymphoma
- B-Cell LymphomaDr. El isAdvanced. Learn about B-Cell Lymphoma.
- Childhood Acute Myeloid Leukemia
- Chronic B-Cell Leukemia (CBCL)
- Chronic Lymphocytic Leukemia (CLL)
- Experienced
- Acinic Cell Carcinoma of Salivary Glands
- Acute Lymphoblastic Leukemia (ALL)
- Acute Myelomonocytic LeukemiaDr. El isExperienced. Learn about Acute Myelomonocytic Leukemia.
- Acute Promyelocytic LeukemiaDr. El isExperienced. Learn about Acute Promyelocytic Leukemia.
- Adenoid Cystic CarcinomaDr. El isExperienced. Learn about Adenoid Cystic Carcinoma.
- Adult Immune ThrombocytopeniaDr. El isExperienced. Learn about Adult Immune Thrombocytopenia.